XTX Topco’s NeuroSense Therapeutics NRSN Stock Holding History

XTX Topco’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-33,706	Closed	-$31K	–	2915
2025 Q1	$31K	Sell	33,706 -8,191	-20%	-$9.06K	﹤0.01%	2070
2024 Q4	$50.3K	Sell	41,897 -4,099	-9%	-$4.71K	﹤0.01%	1896
2024 Q3	$58.4K	Buy	45,996 +13,346	+41%	+$12.7K	﹤0.01%	1675
2024 Q2	$36.6K	Buy	+32,650	New	+$41.6K	﹤0.01%	1541

Other funds holding NRSN

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

XTX Topco's NRSN Position: Q2 2025 in Review

XTX Topco sold out of NeuroSense Therapeutics (NRSN) in Q2 2025, closing a stake of 33,706 shares — an estimated $31K sold.

XTX Topco first reported a position in NRSN in Q2 2024 and held it in 4 quarters. The position peaked at $58.4K in Q3 2024. 17 funds tracked by Wall St. Rank hold NRSN as of Q2 2025.

XTX Topco reported no remaining NeuroSense Therapeutics position as of Q2 2025 after selling out during the quarter.
XTX Topco sold 33,706 NeuroSense Therapeutics shares in Q2 2025, an estimated $31K.
XTX Topco first reported a position in NeuroSense Therapeutics in Q2 2024 and held it in 4 quarters.
XTX Topco's NeuroSense Therapeutics position peaked at $58.4K in Q3 2024.
17 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.